CD39 Expression on T Lymphocytes Correlates With Severity of Disease in Patients With Chronic

Document Type : Original Article

Authors

1 Department of Clinical Pathology,Faculty of Medicine, Sohag University.

2 Department of Clinical and Chemical pathology, Sohag Faculty of Medicine, Sohag University.

3 Department of Clinical Pathology, Faculty of Medicine, Sohag University.

Abstract

Chronic lymphoid leukemia (CLL), is the most common type of leukemia (a type of cancer of the white blood cells) in adults representing 25%-30% of all leukemias, CLL is a disease of adults. Most (>75%) people newly diagnosed with CLL are over the age of 50, and the majority are men, The leukemia is characterized by a clonal expansion of long-lived  mature-appearing B lymphocytes that co-express the CD5, CD19, and CD23 surface antigens.CD39 (ectonucleotidase, NTDPase1) is an ADPase found on the surface of endothelial cells, normal lymphocytes  and other leukocytes, Its principal function on the endothelial cell surface is to decrease platelet activation and recruitment by metabolizing platelet-released adenosine diphosphate (ADP). In leukocytes the enzyme has a variety of  other direct or indirect effects as well, including modulation of cytokine expression and the inflammatory response. The aim of this study to review the role  CD39  in patients with chronic lymphocytic leukemia  and correlate it with the severity of the disease. A total of 5 papers were obtained using the mentioned keywords in the research of all internet-based databases. The total number of cases in all of the studies was 716 cases.The mean age was recorded in 5 papers was 64.7 years. There are different method of detection of CD39 in different studies such as flow cytometry and immunohistochimistry .

1- Byrd and John; "Chronic Lymphocytic Leukemia". Leukemia & Lymphoma Society, Retrieved 24 March 2014
2- Chiorazzi N, Rai KR, Ferrarini M; (2005). "Chronic lymphocytic leukemia". N. Engl. J. Med. 352 (8): 804–15. doi:10.1056/NEJMra041720
3- Deaglio S, Dwyer KM, Gao W and Friedman D, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 2007;204:1257–1265.
4- Hyman MC, Petrovic-Djergovic D and Visovatti SH et al ; Self-regulation of inflammatory cell trafficking in mice by the leukocyte surface apyrase CD39.JClinInvest 2009; 119:1136-49. 13.
5 -Patten PE, Buggins AG, Richards J, et al. CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood 2008;111(10):5173-5181.
6- Chava Perry and Aaron Polliack,2012 ;Regulatory T cells in chronic lymphocytic leukemia: Leukemia & Lymphoma, May 2013; 54(5): 903–904, 2013 Informa UK, Ltd.ISSN:1042-8194print / 1029-2403 onlineDOI: 10.3109/10428194.2012.747681
7-Hallek M; Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017;92:946–965. https://doi.org/10.1002/ajh. 24826
8-John C. Byrd, Stephan Stilgenbauer and Ian W. Flinn Chronic Lymphocytic Leukemia doi: 10.1182/asheducation-2004.1.163 ASH Education Book January 1, 2004 vol. 2004 no. 1 163-183
9-Matutes E, and Polliack A,2000 ; Morphological and immunophenotypic features of chronic lymphocytic leukemia. First published: March 2000 DOI: 10.1046/j.1468-0734.2000.00002.
10-Quiroga MP1, Balakrishnan K, Kurtova AV ,et al;. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: Blood. 2009 Jul 30; 114(5): 1029–1037. Prepublished online 2009 Jun 2. doi:  10.1182/blood-2009-03-212837PMCID: PMC4916941,Lymphoid Neoplasia.
11-Pulte D, Furman RR, Broekman MJ, et al ; CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk 2011;11
12-D'Arena G, Laurenti L, Minervini MM et al (2011) Regulatory Tcell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. Leuk Res 35:363–368
13-Nashwa Khairat, Abousamra Manal Salah El-Din, Eman Hamza Elzahaf ,2015 Ectonucleoside triphosphate diphosphohydrolase-1 (E-NTPDase1/CD39) as a new prognostic marker in chronic lymphocytic leukemiaPages 113-119 | Received 28 Oct 2013, Accepted 18 Mar 2014, Accepted author version posted online: 31 Mar 2014, Published online: 05 Jun 2014
14-Bastid J, Regairaz A, Bonnefoy N, et al ; Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity. Cancer Immunol Res. 2015;3:254–65.